I've written before about GLP1 drugs and hunger. This is a different story. A new NIH funded study just found a second brain pathway these drugs seem to reach, one tied to wanting rather than needing, and it's specific to the newer oral pill class rather than the injectables most people already know.
A team at the University of Virginia, funded by NIH, gene edited mice so their GLP1 receptors more closely resemble human receptors. That step mattered because orforglipron and danuglipron, both oral small molecule GLP1 drugs, are designed for the human receptor, not the native rodent one. The study was published July 25, 2026 in Nature, with NIH's own press release, ScienceDaily, and EurekAlert all independently reporting matching figures.
Dosed mice showed activation in the central amygdala, a desire and reward hub deeper in the brain than these drugs were previously thought to reach, along with reduced dopamine release specifically while the mice ate palatable, non essential food. The already known appetite suppression pathway, running through the hypothalamus and hindbrain, tracked separately and didn't explain this new effect on its own. The two mechanisms look distinct: one dials down hunger, the other appears to dial down the pull of eating purely for pleasure.
This is mouse only data. Even with humanized GLP1 receptors, it hasn't been shown in people, and NIH's own release notes the study was not completed as a clinical trial. There's no independent replication yet either. The dopamine and reward findings describe what happened alongside drug exposure, not proof of exactly how it happens in a human brain, so I wouldn't extrapolate this into "this drug will kill your cravings" claims for actual patients until human studies exist.
If you've wondered why GLP1 drugs seem to quiet the urge to snack and not just the feeling of hunger, this gives that observation an actual mechanism, at least in mice, and at least for the oral small molecule class. It's also a genuine bridge to a storyline I plan to keep watching, since the NIH team is explicitly eyeing follow up studies on cravings for substances beyond food, alcohol and nicotine among them, using the same reward circuit logic.
No. This new reward circuit finding is specific to the oral small molecule GLP1 pills orforglipron and danuglipron. Injectable peptide GLP1 drugs like semaglutide, sold as Ozempic, work primarily through a different, already established hypothalamus and hindbrain pathway. Whether injectable GLP1s also reach this reward circuit wasn't tested here.
Not yet. This is mouse only data. Researchers gene edited the mice to carry humanized GLP1 receptors so the human designed drugs would work correctly, but NIH's own release notes the study was not run as a clinical trial. No human imaging data exists yet to confirm the same circuit lights up in people.
That's the researchers' own next question, not something this study proved. The NIH team is already planning follow up studies on substance use cravings, since the mechanism they found, dampening dopamine during reward driven wanting, is the same kind of circuit implicated in addiction. That's a hypothesis for future research, not a finding of this paper.
Get the Daily Signal in your inbox each morning, verified and no hype, before you even open your phone.